|
|
News Breaks | | | | December 9, 2012 | | 22:11 EDT |  | TKPYY | Takeda highlights data on VELCADE treatment for multiple myeloma
Millennium: The Takeda Oncology company with its parent company Takeda Pharmaceutical announced results from two studies evaluating the safety and efficacy of VELCADE-based therapy. The first study reported data from a meta-analysis of VELCADE retreatment in patients with relapsed and/or refractory, R/R, multiple myeloma, MM. The second study ,'GIMEMA', evaluated VELCADE in combination with thalidomide as maintenance therapy for patients with previously untreated MM. These data were presented at the 54th American Society of Hematology, ASH, Annual Meeting held December 8-11 in Atlanta, GA. “The GIMEMA study continues to affirm the known overall survival benefit of VELCADE-based therapy in patients with previously untreated multiple myeloma,” said Karen Ferrante, M.D., Chief Medical Officer, Millennium. | |
|
News For TKPYY From The Last 14 Days Check below for free stories on TKPYY the last two weeks. |
|
|
| May 21, 2013 | | 18:56 EDT | | TKPYY | On The Fly: After Hours Movers
 Subscribe for More Information | | | 17:34 EDT | | TKPYY | AMAG says Takeda recalling one batch of Rienso from Swiss market
Subscribe for More Information | |
|
|
|
|
|
|
